All In Biotech

Drug Trial Radar · NCT03547583

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of the Oral sGC stImulator Vericiguat to Improve Physical Functioning in Activities of Daily Living in Patients With Heart Failure and Preserved Ejection Fraction (VITALITY-HFpEF)

Last checked: Nov 20, 2026Latest source record: Jan 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 789 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

789

Actual

Start

Jun 15, 2018

Primary completion

Oct 15, 2019

Study completion Nov 4, 2019

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Canadian VIGOUR Centre; Duke Clinical Research Institute
First posted
Jun 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Conditions

  • Chronic Heart Failure With Preserved Ejection Fraction

Interventions

  • Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tabletsDrug

    Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.

  • PlaceboDrug

    Placebo and sham up-titration at weeks 2, 4, and 6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in KCCQ Physical Limitation Score From Baseline to Week 24Time frame: From baseline to Week 24

Locations

177 sites in 21 countries. Site status is shown where the registry gives one.

  • WestSide Medical

    Beverly Hills, California

  • Capitol Interventional Cardiology

    Carmichael, California

  • Interventional Cardiology Medical Group

    West Hills, California

  • Penrose-St. Francis Health Services

    Colorado Springs, Colorado

  • Cardiology Associates of Fairfield County, PC

    Trumbull, Connecticut

  • Cardiology Associates Of South Florida PA

    Boynton Beach, Florida

  • Cardiovascular and Vein Center of Florida

    Bradenton, Florida

  • Cardiology Associates Research Company

    Daytona Beach, Florida

  • LifeSpring Research Foundation, LLC

    Miami, Florida

  • Southwest Florida Research

    Naples, Florida

  • East Coast Institute for Research, LLC

    Saint Augustine, Florida

  • Cardiology Partners

    Wellington, Florida

  • Fox Valley Clinical Research Center, LLC

    Aurora, Illinois

  • Advocate Condell Medical Center

    Libertyville, Illinois

  • Reid Health

    Richmond, Indiana

  • Research Integrity, LLC

    Owensboro, Kentucky

  • Heart Clinic of Hammond

    Hammond, Louisiana

  • Anne Arundel Health System

    Annapolis, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Riser Medical Associates

    Picayune, Mississippi

  • St. Louis Heart & Vascular, PC

    St Louis, Missouri

  • Glacier View Research Institute

    Kalispell, Montana

  • Bryan Heart

    Lincoln, Nebraska

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Capital Area Research, LLC

    Camp Hill, Pennsylvania

  • Carolina Heart Specialists

    Lancaster, South Carolina

  • Stern Cardiovascular Center

    Germantown, Tennessee

  • Clinical Advancement Center, PLLC

    San Antonio, Texas

  • Corporation Lane Research Center

    Virginia Beach, Virginia

  • Inst. de Cardiología de Corrientes Juana Francisca Cabral

    Corrientes, Argentina

  • Centro de Investigaciones Clinicas del Litoral

    Santa Fe, Argentina

  • Clínica DIM

    Ramos Mejía, Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas San Nicolás

    San Nicolás de los Arroyos, Buenos Aires, Argentina

  • Centro de Investigaciones Clínicas

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Centro de Medicina Integral e Investigacion Clínica

    CABA, Ciudad Auton. de Buenos Aires, Argentina

  • Centro de Especialidades Médicas

    Villa Luro, Ciudad Auton. de Buenos Aires, Argentina

  • Sanatorio Parque S.A.

    Rosario, Santa Fe Province, Argentina

  • Zentrum f. klinische Studien Dr. Hanusch GmbH

    Vienna, Austria

  • Universitätsklinikum AKH Wien

    Vienna, Austria

  • Klinik Floridsdorf - Krankenhaus Nord

    Vienna, Austria

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.